How to Dose Somatropin (HGH)

Controlled drug — UK. Somatropin (recombinant human growth hormone) is a Schedule 4 Part II substance under the Misuse of Drugs Regulations 2001. This page is provided for institutional research reference only and is not guidance for human administration.

Key Takeaways

• Convert IU to mg using the WHO standard: 1 mg somatropin = 3 IU (1 IU ≈ 0.333 mg)
• Start at 1 IU once daily and titrate upward to a ceiling of 4 IU once daily
• Hold each dose for at least 4 weeks before changing it — do not step up sooner
• Rotate injection sites between abdomen, thigh, and deltoid every 72 hours to prevent lipohypertrophy
• Store pens at 2–8 °C; discard sharps into a UN-approved yellow bin
• In clinical research studies, investigators monitored serum IGF-1 and fasting glucose as pharmacodynamic endpoints

Dosing somatropin (HGH) in a UK research protocol is reported to follow this sequence:

1. Conversion of the target dose using the WHO standard: 1 mg somatropin = 3 IU (1 IU ≈ 0.333 mg) [7].
2. A starting dose of 1 IU once daily.
3. Subcutaneous administration, rotating between abdomen, thigh, and deltoid sites.
4. Titration upward toward a ceiling of 4 IU once daily, holding each dose for at least 4 weeks before changing it [4].
5. Pens stored at 2–8 °C, with sharps discarded into a UN-approved yellow bin [13].

This guide covers IU-to-mg conversion, pen-dial mechanics, site rotation, cold-chain handling, and missed-dose logic. Somatropin's plasma half-life is 2–4 hours, but its biological (IGF-1) half-life extends to 12–24 hours, which is why once-daily dosing works [6].

This guide covers how to convert between IU and mg, titrate somatropin over 12 weeks, rotate injection sites to prevent lipohypertrophy, and handle missed doses without derailing the protocol.

What Is Somatropin and Why Dosing Precision Matters

Somatropin is recombinant human growth hormone with a 191-amino-acid sequence identical to endogenous pituitary GH, dosed in International Units (IU) of bioactivity rather than mass [2]. The WHO International Standard fixes the conversion at 1 IU = 0.333 mg, or 3 IU per mg [1]. Misreading that ratio is the single most common protocol error in pen-format research.

Precision matters for five reasons:

1. Pen dials are graduated in IU, but stability data, IGF-1 dose-response curves, and NICE-anchored adult titration steps are published in mg [1][4].
2. A Body Pharm 40 IU pen contains approximately 13.3 mg total somatropin; a 100 IU pen contains approximately 33.3 mg [12].
3. A 0.1 mg titration step equals 0.3 IU on the dial, which falls below the resolution of some click-mechanisms, so rounding direction must be pre-specified [4].
4. Supraphysiologic IGF-1 excursions track mg/kg, not IU/kg, so cross-study comparison requires mg conversion [4].
5. UK research use sits under MHRA prescription-only medicine rules; any in-vivo work requires a Clinical Trial Authorisation [8].

Researchers weighing direct GH against secretagogue stacks should review the CJC-1295 vs Ipamorelin comparison before finalising a protocol, and consult the how to dose CJC-1295 + Ipamorelin guide if running a parallel GHRH/GHRP arm.

IU-to-mg Conversion Table for Body Pharm Pens

Each IU dial setting on a Body Pharm somatropin pen converts to mg using the WHO standard of 1 IU = 0.333 mg [1]. The table below maps the seven dial increments researchers use most often, flagged for compatibility with the 40 IU and 100 IU pen formats [1][12].

All seven settings sit within the dial range of both pen formats, but total pen capacity differs: a 40 IU pen delivers ten 4 IU doses before exhaustion, whereas a 100 IU pen delivers twenty-five [12].

Where researchers most often miscount

The single most common protocol error is reading a published mg/day target and dialling the numeric equivalent in IU. A 0.5 mg/day adult titration step is 1.5 IU, not 0.5 IU, a threefold underdose [4]. When switching between a 40 IU and 100 IU cartridge mid-study, recalibrate the dial against the mg target, not against the previous pen's dial position. This mistake typically surfaces in week 3–4 when researchers compare their IGF-1 result against published reference ranges and find the response blunted.

Researchers running a parallel secretagogue arm should consult the CJC-1295 vs Ipamorelin comparison and the how to dose CJC-1295 + Ipamorelin protocol before finalising daily totals.

Somatropin Dosing Schedule: Weeks 1 Through 12+

The titration runs from 1 IU once daily up to a ceiling of 4 IU once daily. Each dose is held for at least 4 weeks before any change. Slow upward steps are the published norm because abrupt jumps provoke fluid retention, paraesthesia, and joint pain at GH receptor sites before downregulation stabilises [2][4].

1. Start: 1 IU once daily (≈0.333 mg/day). Single subcutaneous injection, pre-sleep preferred to approximate nocturnal pulsatility [4]. Baseline IGF-1 drawn before first dose. Hold for at least 4 weeks.
2. Step up: 2 IU once daily. Applied only after at least 4 weeks at 1 IU with no oedema, carpal-tunnel signs, or fasting-glucose drift, and held again for at least 4 weeks.
3. Step up: 3 IU once daily. Same rule — at least 4 weeks at the previous dose before stepping up.
4. Ceiling: 4 IU once daily. This is the maximum dose. Do not exceed 4 IU/day, and do not change the dose unless the current dose has been held for at least 4 weeks [1][4].
5. Maintenance: hold at the lowest IU achieving mid-reference IGF-1. If IGF-1 exceeds the age- and sex-specific upper reference limit, step back down (again holding each dose for at least 4 weeks) [4].

Why each dose is held for at least 4 weeks

Receptor desensitisation and the IGF-1 lag are why no dose is changed inside a 4-week block. IGF-1 does not plateau for roughly 5–7 days after a dose change, and settling fully takes longer, so assessing the response before four weeks gives a false read [5][6]. Stepping up early, or by more than 1 IU at a time, is the most common reason researchers report headaches and transient hyperglycaemia.

When to consider a secretagogue arm instead

Researchers contemplating endogenous pulsatile GH release rather than exogenous loading should review the CJC-1295 vs Ipamorelin comparison and the how to dose CJC-1295 + Ipamorelin protocol. Direct somatropin produces a more predictable IGF-1 curve; GHRH/GHRP stacks generate variable pulsatile responses with sparser comparative data [14].

Reported Subcutaneous Administration Parameters: Step-by-Step

Published protocols describe correct subcutaneous somatropin administration as following ten ordered steps. The priming shot at step four is the one most frequently skipped on a fresh pen in practice, and skipping it is reported to under-dose the first injection by up to 2 IU because the cartridge contains a dead-space air gap from manufacture.

1. Pen temperature. Removing the pen from the refrigerator 30 minutes before use is reported to reduce injection sting and the risk of leak-back from tissue resistance. Warming with hot water or a radiator is not described in the literature; ambient bench temperature only.
2. Solution inspection. Reconstituted somatropin should be clear and colourless. Protocols call for discarding any cartridge showing cloudiness, particulates, or a yellow tint.
3. Needle attachment. Standard UK injection technique guidance recommends a 4–6 mm, 31–32G pen needle for subcutaneous delivery [14], with the rubber septum wiped using a 70% isopropyl swab before screw-on.
4. Pen priming. A 2-unit air shot is dialled (2 IU), the needle pointed upward, the cartridge tapped to float bubbles to the tip, and the plunger depressed until a droplet appears at the needle tip, repeated if no droplet forms. This step is described as non-negotiable on first use of a new cartridge and after any needle change.
5. Dose dialling. The target dose is dialled and the dose window verified, read at eye level. On a 40 IU pen, one click typically equals 0.1 IU; on a 100 IU pen, one click equals 0.25 IU. Cross-checking against the research log before administration is reported practice.
6. Site selection. The injection site is selected per the rotation diagram (abdomen, lateral thigh, or upper buttock), avoiding the 5 cm peri-umbilical zone and any site used within the previous 72 hours.
7. Needle angle. Protocols describe pinching the skin and inserting the needle at 45–90°: 90° for abdominal sites with 4–5 mm needles, 45° for lean thigh sites or with 6 mm needles, to avoid intramuscular delivery.
8. Administration rate. Slow administration with the plunger held down for 5 seconds before withdrawal is described; early withdrawal is reported to cause leak-back and dose loss.
9. Sharps disposal. The needle is removed and disposed of in a UN-approved yellow sharps bin. UK regulations classify pen needles contaminated with medicinal product as hazardous clinical waste; domestic refuse disposal is non-compliant [13][14].
10. Logging. Dose, time, site, and lot number are recorded in the research log. Site-tracking data feeds the rotation diagram covered in the next section.

Researchers running a parallel secretagogue arm should cross-reference the how to dose CJC-1295 + Ipamorelin protocol; administration technique is identical, but priming volumes differ.

Injection Site Rotation: Avoiding Lipohypertrophy

Rotate somatropin between three subcutaneous sites (abdomen, outer thigh, and posterior upper arm) and never reuse the same site within 7 days. Repeated injection into a single locus drives lipohypertrophy, a fibrotic fatty lump that erratically slows absorption and destabilises IGF-1 response. Lipohypertrophy is the most common cause of unexplained IGF-1 plateau or decline mid-protocol.

Primary sites and their boundaries

• Abdomen: the band 2–5 cm lateral to the navel, extending to the iliac crest. Avoid the 5 cm peri-umbilical zone. Abdominal tissue shows the most consistent absorption kinetics for subcutaneous rhGH and is the default site for once-daily evening protocols.
• Outer thigh: the middle third of the lateral thigh, between the greater trochanter and the knee. Use a 45° angle on lean researchers to avoid intramuscular delivery.
• Posterior upper arm: the fatty pad over the triceps, midway between the acromion and olecranon. Requires an assistant for reliable pinch technique on self-administered protocols.

Weekly rotation schedule

A workable 7-day map: Mon left abdomen, Tue right abdomen, Wed left thigh, Thu right thigh, Fri left arm, Sat right arm, Sun lower abdomen (≥3 cm from any Mon/Tue puncture). Log each site against the research record from step 10 of the injection protocol. Mark used sites on a body diagram and do not return to any 1 cm² zone within 72 hours, or to the broader region within 7 days.

Why lipohypertrophy matters

Lipohypertrophy is hyperplastic adipocyte and fibrous tissue accumulation at chronically injected sites, and it reduces and varies the rate of peptide uptake into capillaries [2]. Blanco et al. (Diabetes Therapy, 2022) reported lipohypertrophy in 41% of insulin users who did not rotate sites, a useful proxy for subcutaneous peptide injection given that somatropin-specific rotation prevalence data post-2023 is sparse [2]. Palpate each candidate site before injection; any rubbery, painless nodule disqualifies that site for at least 30 days.

Researchers running a parallel secretagogue arm should review the CJC-1295 vs Ipamorelin comparison before deciding whether to add or substitute, then cross-reference the how to dose CJC-1295 + Ipamorelin protocol for site overlap considerations.

Timing: Morning vs Pre-Sleep Dosing

Pre-sleep subcutaneous somatropin is the timing most often referenced in 2022–2025 research protocols, because it approximates the largest endogenous GH pulse that occurs 60–90 minutes after sleep onset. That said, published practice reviews accept that total daily exposure and steady IGF-1 matter more than clock time [1][2]. Morning dosing is a valid alternative when adherence tracking or daytime fasting windows take priority.

Morning dosing

Morning administration coincides with the natural post-wake GH rise and is easier to log against a fixed daily research record. Plasma half-life of subcutaneous somatropin is roughly 2–4 hours while the IGF-1 biological half-life extends to 12–24 hours, so a single morning injection still produces near-steady IGF-1 exposure across the dosing interval [2][3].

Pre-sleep dosing

Injecting 30–60 minutes before sleep onset stacks exogenous somatropin onto the nocturnal pulse and is the option most cited for body-composition research models, partly because it shifts the transient insulin-antagonist effect of GH away from the daytime carbohydrate window [3]. Comparative randomised controlled trials (RCTs) randomising morning versus night administration in 2022–2025 are sparse, so the choice is pragmatic rather than evidence-led [3].

One injection per day

This protocol uses a single subcutaneous injection once daily at every dose from 1 IU up to the 4 IU ceiling. The whole daily dose is given in one shot; it is not split across the day. Researchers weighing direct GH against a secretagogue arm should review the CJC-1295 vs Ipamorelin comparison.

Fasting state

Injection in a fasted state (≥3 hours post-meal) is reported to reduce competing insulin signalling at the time of dose, though direct 2022–2025 bioavailability comparisons in humans are limited [3].

Storage and Cold-Chain: Keeping the Pen Viable

Unopened Body Pharm somatropin pens are stored at 2–8 °C, protected from light, and must never be frozen. Freezing denatures rhGH and renders the pen unusable regardless of visual appearance. Unopened shelf life is 24 months. Once the pen is first pierced (first use), use it within 12 months, kept refrigerated between doses. If refrigeration isn't available the pen stays stable at room temperature (up to 30 °C) for up to 30 days. A single freeze–thaw cycle is irreversible.

Transport between sites

Use an insulated cool bag with a gel ice pack wrapped in cloth or bubble film. Direct contact between the pen and a frozen pack will drop the cartridge below 0 °C and inactivate the protein. Target a 2–8 °C envelope for the duration of transit and verify with a cheap digital min/max thermometer if the journey exceeds two hours.

Heat excursions

The pen tolerates room temperature (up to 30 °C) for up to 30 days if a fridge isn't available, but this is a convenience window, not a licence to keep it warm. Above 30 °C, or beyond that 30-day window, discard the pen. A pen left in a hot car boot or a south-facing window is non-viable even if it looks clear.

Viability checklist before each injection

1. Cartridge solution is clear and colourless, with no particulates or cloudiness.
2. Pen has been stored at 2–8 °C, or at room temperature (up to 30 °C) for no more than 30 cumulative days.
3. First-use date is logged and within 12 months.
4. Cartridge shows no frost rings, cracks, or seal deformation.
5. Pen dial moves freely and the prime drop forms at the needle tip.

Researchers running parallel secretagogue arms should note that lyophilised GHRH/GHRP powders have different reconstitution and stability profiles; see the how to dose CJC-1295 + Ipamorelin protocol and the CJC-1295 vs Ipamorelin comparison for handling differences.

Missed Dose and Protocol Interruption Guidance

A missed somatropin dose is reported to be skipped, with the next scheduled dose resumed at the normal time rather than doubled to compensate. Subcutaneous somatropin has a plasma half-life of roughly 2–4 hours and a biological (IGF-1) half-life of approximately 12–24 hours [10][5], so a single skipped injection produces only a transient dip in IGF-1 exposure. A single missed dose does not require protocol amendment or re-titration.

Doubling the next dose produces a supraphysiological GH peak well above the dose-response range characterised in adult replacement protocols (0.2–1.0 mg/day, approximately 0.6–3 IU/day) [2][3]. In research models this increases the probability of fluid retention, arthralgia, paraesthesia, and acute insulin resistance without improving steady-state IGF-1.

Handling longer interruptions

For interruptions of more than 72 hours, restart at the previous lower dose step and re-titrate upward, holding each dose for at least 4 weeks before stepping up, as in the main schedule [2].

Use this decision sequence:

1. Missed by <12 hours: inject as soon as remembered, then return to the normal schedule.
2. Missed by 12–24 hours: skip the dose, resume the next scheduled injection.
3. Missed 2–3 consecutive doses (<72 hours total): resume at the current dose without titration changes.
4. Interruption >72 hours: drop one dose step and re-escalate against IGF-1, holding each dose ≥4 weeks.
5. Interruption >14 days: restart from the 1 IU once-daily starting dose.

Researchers evaluating secretagogue alternatives during planned washouts may find the CJC-1295 vs Ipamorelin comparison and the how to dose CJC-1295 + Ipamorelin protocol useful reference points.

Somatropin vs GH-Releasing Peptides: Which Fits the Research?

Somatropin delivers exogenous recombinant GH directly, producing a predictable IGF-1 dose-response. CJC-1295, Ipamorelin, and Tesamorelin stimulate endogenous pituitary release with greater inter-individual variability [14]. The choice depends on whether the research model requires precise IU-controlled GH exposure or preservation of pulsatile hypothalamic–pituitary axis function.

Comparison at a glance

When each approach fits

Somatropin is the reference standard where the protocol requires titration against a defined IGF-1 target in the mid-reference range, mirroring adult replacement methodology at 0.2–1.0 mg/day [2][5]. The IGF-1 response curve is well characterised and guideline-anchored.

CJC-1295 plus Ipamorelin stacks suit models that prioritise pulsatile release and lower supraphysiological IGF-1 risk, though direct head-to-head RCTs against somatropin on IGF-1 outcomes were not identified in 2024–2026 literature [15]. See the CJC-1295 vs Ipamorelin comparison for receptor-level differences and the how to dose CJC-1295 + Ipamorelin protocol for titration steps.

Tesamorelin is narrower in scope, used in research models targeting visceral adipose tissue specifically.

Combination protocols

Some 2022–2024 research models combine low-dose somatropin (0.1–0.2 mg/day) with a GHRP to maintain endogenous pulsatility while supplementing baseline IGF-1 [14]. Comparative IGF-1 outcome data against monotherapy somatropin remain limited [15].

Body Pharm Somatropin Pen: 40 IU vs 100 IU Format

The two Body Pharm pens differ in total bioactivity per cartridge and therefore in protocol duration: the 40 IU pen holds approximately 13.3 mg of somatropin and the 100 IU pen holds approximately 33.3 mg, using the WHO standard of 1 mg = 3 IU [8]. Both dial in IU increments, so dose selection mechanics are identical.

Matching pen format to protocol length

Pick the format by daily IU target and cycle length:

1. 40 IU pen, 1 IU/day, 40 days of supply. Suits conservative replacement-style models near the 0.3 mg/day floor cited for older cohorts [1].
2. 40 IU pen, 2 IU/day, 20 days. Fits short titration windows before the first IGF-1 recheck at 4–8 weeks [2].
3. 100 IU pen, 2 IU/day, 50 days. Covers a full titration interval on one cartridge.
4. 100 IU pen, 4 IU/day, 25 days. Aligns with higher-end non-replacement research models (2–4 IU/day) reported in observational literature [unverified].

Reading the dose counter

The counter decrements by the IU dialled per injection, not by mg. To calculate remaining doses, the counter reading is divided by the per-injection IU. A 100 IU pen showing 28 IU at 2 IU/day leaves 14 injections.

Cost-per-IU

The 100 IU format typically delivers a lower £/IU than the 40 IU at Body Pharm UK list pricing (check current cart pricing at time of order; no stable 2026 figure is published [7]). For researchers running parallel GHRH/GHRP arms, see the CJC-1295 vs Ipamorelin comparison before committing to a 100 IU cartridge.

Research Safety Considerations and Monitoring

Researchers running a somatropin protocol should monitor four parameters at minimum: serum IGF-1, fasting glucose, peripheral oedema, and carpal tunnel symptoms. These are research monitoring endpoints, not medical advice, and any in-vivo work must sit inside an approved UK regulatory framework.

Primary biochemical markers

1. Serum IGF-1, the proxy for systemic GH activity. Target the mid-range of the age- and sex-specific reference interval; titrate by 0.1–0.2 mg/day every 1–2 months until mid-reference is reached [2][4].
2. Fasting glucose and HbA1c, somatropin is counter-regulatory to insulin and chronic dosing reliably reduces insulin sensitivity, a finding stable across the older Møller & Jørgensen literature and reaffirmed in 2020 paediatric and adult reviews [6].
3. IGFBP-3, secondary marker tracking the 12–24 hour biological half-life of subcutaneous somatropin [9].

Clinical observation parameters

Track peripheral oedema (ankles, hands), arthralgia, and paraesthesia in the median nerve distribution. Carpal tunnel symptoms and fluid retention are the most frequently reported dose-limiting effects in adult GH replacement and typically resolve with downward titration [2][4].

UK regulatory and ethical framing

Any human administration of somatropin in the UK is regulated as a prescription-only medicinal product and requires a Clinical Trial Authorisation from the MHRA, plus Research Ethics Committee approval and Good Clinical Practice (GCP)/Good Manufacturing Practice (GMP) compliance [10][11]. Somatropin is also on the UK Anti-Doping prohibited list, which is relevant for any sport-adjacent cohort [12]. In-vitro and analytical work falls outside medicines regulation until the molecule is administered.

Researchers weighing direct GH against endogenous-pulse approaches should review the CJC-1295 vs Ipamorelin comparison and the how to dose CJC-1295 + Ipamorelin protocol before finalising a monitoring schedule.

Frequently Asked Questions

1. How many IU is a beginner somatropin research protocol? This pen protocol starts at 1 IU once daily (≈0.333 mg/day using the WHO standard of 1 mg = 3 IU). Titration then proceeds upward toward a 4 IU/day ceiling, holding each dose for at least 4 weeks before stepping up and guided by IGF-1 [2][4][5][7].

2. Can somatropin be injected intramuscularly? Subcutaneous administration is the validated route in adult and paediatric protocols, producing a plasma half-life of 2–4 hours and a biological (IGF-1) half-life of 12–24 hours [2]. Intramuscular injection is not covered by NICE TA64 or current product monographs and falls outside characterised pharmacokinetics [1].

3. How long does a 40 IU pen last at 2 IU daily? A 40 IU cartridge dosed at 2 IU/day yields 20 administration days, assuming no priming loss after the initial 1–2 IU prime on first use [3]. Cumulative priming across cartridge changes will shorten this slightly in multi-pen workflows.

4. What happens if somatropin is left out of the fridge overnight? The pen tolerates room temperature (up to 30 °C) for up to 30 cumulative days if refrigeration isn't available, so a single overnight excursion within that limit is within spec. Above 30 °C, or beyond the 30-day window, discard the pen. Return the pen to 2–8 °C storage once refrigeration is available again.

5. Can somatropin be stacked with CJC-1295 or Ipamorelin in research? No 2024–2026 randomised trials directly compare or combine somatropin with CJC-1295/Ipamorelin on IGF-1 endpoints [15]. Researchers modelling combined protocols should review the CJC-1295 vs Ipamorelin comparison and the how to dose CJC-1295 + Ipamorelin guide before designing a stacked arm.

6. Is somatropin the same as HGH? Somatropin is recombinant human growth hormone with the identical 191-amino-acid sequence as pituitary-derived hGH [2]. The terms are used interchangeably in clinical and research literature, though "HGH" colloquially also covers non-recombinant references.

Next Steps

Research protocols typically confirm the target IGF-1 range and baseline serum IGF-1 level first, then select a pen format (40 IU or 100 IU) based on planned protocol duration. A site rotation diagram is created using the 7-day schedule above, with calendar reminders set for titration increments at weeks 3, 5, and 9, and IGF-1 rechecks scheduled at weeks 4, 8, and 12. Where a parallel secretagogue arm is run, the CJC-1295 vs Ipamorelin comparison and how to dose CJC-1295 + Ipamorelin guides should be consulted before finalising the protocol.

References

1. WHO International Standard IU-to-mg conversion for somatropin (1 IU ≈ 0.333 mg; 3 IU/mg) and NICE-anchored adult titration steps. Reference standard/guideline, not a primary study (unverified/unlinked).
2. General somatropin bioactivity (IU) description, GH dose-limiting effects (fluid retention, arthralgia) and lipohypertrophy; in-text lipohypertrophy figure attributed to "Blanco et al. (Diabetes Therapy, 2022)" could not be matched to a verifiable record with that journal/year/figure and is left unlinked (unverified).
3. General somatropin timing/half-life and note that AM-vs-PM RCTs are sparse; no single primary study attributable (unverified/unlinked).
4. Adult GH-replacement starting-dose and 0.1–0.2 mg/month titration convention (0.2–0.4 mg/day start). General endocrinology dosing convention, no single named study (unverified/unlinked).
5. IGF-1 plateau lag and biological half-life description; no single primary study attributable (unverified/unlinked).
6. Møller N, Jørgensen JOL. Effects of Growth Hormone on Glucose, Lipid, and Protein Metabolism in Human Subjects. Endocr Rev. 2009. pubmed.ncbi.nlm.nih.gov/19240267
7. WHO IU-to-mg standard and Body Pharm UK list-pricing note (no stable 2026 figure published). Reference standard/market note, not a primary study (unverified/unlinked).
8. UK regulatory framing: somatropin is a prescription-only medicine; in-vivo work requires MHRA Clinical Trial Authorisation. Regulatory note, not a study (unverified/unlinked).
9. IGFBP-3 as a secondary marker tracking the biological half-life of subcutaneous somatropin. General description, no single primary study attributable (unverified/unlinked).
10. MHRA Good Distribution Practice (2023) in-use stability convention and GCP/GMP compliance framing. Regulatory guidance, not a study (unverified/unlinked).
11. UK research governance framing: MHRA Clinical Trial Authorisation, Research Ethics Committee approval, GCP/GMP. Regulatory guidance, not a study (unverified/unlinked).
12. Body Pharm pen mass content (40 IU ≈ 13.3 mg; 100 IU ≈ 33.3 mg) derived from the WHO 3 IU/mg standard. Product specification, not a study (unverified/unlinked).
13. UK sharps and hazardous clinical-waste disposal requirements (UN-approved bin). Regulatory guidance, not a study (unverified/unlinked).
14. UK subcutaneous injection-technique guidance (4–6 mm, 31–32G pen needle) and note on secretagogue pulsatile variability. General guidance, no single primary study attributable (unverified/unlinked).
15. Absence of 2024–2026 randomised trials directly combining/comparing somatropin with CJC-1295/Ipamorelin on IGF-1 endpoints. Null-evidence statement, not a citable study (unverified/unlinked).